CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
Ra-223 Dichloridedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01833520
NCT01833520Phase 2Completed
CompareCT.gov

Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

M.D. Anderson Cancer Center·interventional·Posted Apr 17, 2013·Updated Feb 2, 2021

In Brief

A Phase 2 clinical trial evaluating Ra-223 Dichloride for Sarcoma. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to find the highest tolerable dose of radium-223 dichloride that can be given to patients with osteosarcoma. Radium-223 chloride is designed to work like radiation therapy in cells that are actively making bone. It is designed to target new bone growth in and around bone cancer and may kill cancer cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma
CountriesUnited States
CollaboratorsBayer

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 17, 2013
Enrollment StartOct 16, 2013
Primary CompletionApr 8, 2020
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 13.2 years ago

Interventions

Ra-223 Dichloridedrug

Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle. Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I.